Rolling maneuver load alleviation using active controls

Rolling Maneuver Load Alleviation (RMLA) was demonstrated on the Active Flexible Wing (AFW) wind tunnel model in the LaRC Transonic Dynamics Tunnel. The design objective was to develop a systematic approach for developing active control laws to alleviate wing incremental loads during roll maneuvers. Using linear load models for the AFW wind-tunnel model which were based on experimental measurements, two RMLA control laws were developed based on a single-degree-of-freedom roll model. The RMLA control laws utilized actuation of outboard control surface pairs to counteract incremental loads generated during rolling maneuvers and roll performance. To evaluate the RMLA control laws, roll maneuvers were performed in the wind tunnel at dynamic pressures of 150, 200, and 250 psf and Mach numbers of .33, .38, and .44, respectively. Loads obtained during these maneuvers were compared to baseline maneuver loads. For both RMLA controllers, the incremental torsion moments were reduced by up to 60 percent at all dynamic pressures and performance times. Results for bending moment load reductions during roll maneuvers varied. In addition, in a multiple function test, RMLA and flutter suppression system control laws were operated simultaneously during roll maneuvers at dynamic pressures 11 percent above the open-loop flutter dynamic pressure

DAC-3 Pointing Stability Analysis Results for SAGE 3 and Other Users of the International Space Station (ISS) Payload Attachment Sites (PAS)

The purpose of this paper is to provide final results of a pointing stability analysis for external payload attachment sites (PAS) on the International Space Station (ISS). As a specific example, the pointing stability requirement of the SAGE III atmospheric science instrument was examined in this paper. The instrument requires 10 arcsec stability over 2 second periods. SAGE 3 will be mounted on the ISS starboard side at the lower, outboard FIAS. In this engineering analysis, an open-loop DAC-3 finite element model of ISS was used by the Microgravity Group at Johnson Space Flight Center to generate transient responses at PAS to a limited number of disturbances. The model included dynamics up to 50 Hz. Disturbance models considered included operation of the solar array rotary joints, thermal radiator rotary joints, and control moment gyros. Responses were filtered to model the anticipated vibration attenuation effects of active control systems on the solar and thermal radiator rotary joints. A pointing stability analysis was conducted by double integrating acceleration transient over a 2 second period. Results of the analysis are tabulated for ISS X, Y, and Z Axis rotations. These results indicate that the largest excursions in rotation during pointing occurred due to rapid slewing of the thermal radiator. Even without attenuation at the rotary joints, the resulting pointing error was limited to less than 1.6 arcsec. With vibration control at the joints, to a maximum 0.5 arcsec over a 2 second period. Based on this current level of model definition, it was concluded that between 0 - 50 Hz, the pointing stability requirement for SAGE 3 will not be exceeded by the disturbances evaluated in this study

Wearing-off at the end of natalizumab dosing interval and risk of MS disease activity: A prospective 1-year follow-up study

Natalizumab effectively prevents disease activity in relapsing-remitting multiple sclerosis by binding α4 integrin and inhibiting leukocyte migration to the central nervous system. We recently reported an association between low natalizumab receptor occupancy and subjective wearing-off symptoms at the end of the 4-week dosing interval. Here, we aimed to evaluate the short-term risk of disease activity in a 1-year prospective follow-up of the same patient cohort (n = 40). We found that all patients available for follow-up after one year (n = 35) fulfilled the criteria for no evidence of disease activity (NEDA). Thus, wearing-off symptoms were not associated with increased short-term risk of disease activity. Longer follow-up in a larger patient cohort is required to establish whether therapeutic efficacy is maintained in patients with wearing-off symptoms.publishedVersio

Neurofilament light chain as a biomarker in multiple sclerosis

Due to the unpredictable course and heterogenous treatment response in multiple sclerosis (MS), there is a clear need for biomarkers that reflect disease activity in the clinical follow-up of these patients. Neurofilaments are neuron-specific components of the cytoskeleton that can be assayed in different body compartments. They have been explored as potential biomarkers for many years. Neurofilament light chain (NF-L) appears the most promising biomarker in MS patients, and there is now little doubt that NF-L should have a role in the follow-up of MS patients. Newer assays and techniques for NF-L detection available in serum samples confirms the usefulness of NF-L as a biomarker. Nevertheless, there is still a need for prospective studies, and studies to determine clinical useful cut-off values. This review evaluates the strengths and weaknesses of NF-L as a biomarker in patients with MS.publishedVersio

Active load control during rolling maneuvers

A rolling maneuver load alleviation (RMLA) system has been demonstrated on the active flexible wing (AFW) wind tunnel model in the Langley Transonic Dynamics Tunnel (TDT). The objective was to develop a systematic approach for designing active control laws to alleviate wing loads during rolling maneuvers. Two RMLA control laws were developed that utilized outboard control-surface pairs (leading and trailing edge) to counteract the loads and that used inboard trailing-edge control-surface pairs to maintain roll performance. Rolling maneuver load tests were performed in the TDT at several dynamic pressures that included two below and one 11 percent above open-loop flutter dynamic pressure. The RMLA system was operated simultaneously with an active flutter suppression system above open-loop flutter dynamic pressure. At all dynamic pressures for which baseline results were obtained, torsion-moment loads were reduced for both RMLA control laws. Results for bending-moment load reductions were mixed; however, design equations developed in this study provided conservative estimates of load reduction in all cases

CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration

The pathogenesis of Yo‐mediated paraneoplastic cerebellar degeneration (PCD) is unclear. We applied cerebrospinal fluid and serum from PCD patients as well as CDR2 and CDR2L antibodies to neuronal tissue, cancer cell lines, and cells transfected with recombinant CDR2 and CDR2L to elucidate which is the major antigen of Yo antibodies. We found that Yo antibodies bound endogenous CDR2L, but not endogenous CDR2. However, Yo antibodies can bind the recombinant CDR2 protein used in routine clinical testing for these antibodies. Because Yo antibodies only bind endogenous CDR2L, we conclude that CDR2L is the major antigen of Yo antibodies in PCD.publishedVersio

G1m1 predominance of intrathecal virus-specific antibodies in multiple sclerosis

We have previously shown that plasmablasts of the G1m1 allotype of IgG1 are selectively enriched in the cerebrospinal fluid of G1m1/G1m3 heterozygous patients with multiple sclerosis, whereas both allotypes are equally used in neuroborreliosis. Here, we demonstrate a strong preference for the G1m1 allotype in the intrathecal humoral immune responses against measles, rubella, and varicella zoster virus in G1m1/G1m3 heterozygous multiple sclerosis patients. Conversely, intrathecally synthesized varicella zoster virus‐specific IgG1 in varicella zoster virus meningoencephalitis comprised both allotypes. This implies that G1m1 B cells are selected to the central nervous system of multiple sclerosis patients regardless of specificity and suggests that an antigen‐independent mechanism could drive the intrathecal humoral immune response.publishedVersio

Design and Analysis of Outer Mold Line Close-outs for the Max Launch Abort System (MLAS) Flight Experiment

In 2007, the NASA Exploration Systems Mission Directorate (ESMD) chartered the NASA Engineering Safety Center (NESC) to demonstrate an alternate launch abort concept as risk mitigation for the Orion project's baseline "tower" design. On July 8, 2009, a full scale, passive aerodynamically stabilized Max Launch Abort System (MLAS) pad abort demonstrator was successfully launched from NASA Goddard Space Flight Center's Wallops Flight Facility. Aerodynamic close-outs were required to cover openings on the MLAS fairing to prevent aerodynamic flow-through and to maintain the MLAS OML surface shape. Two-ply duct tape covers were designed to meet these needs. The duct tape used was a high strength fiber reinforced duct tape with a rubberized adhesive that demonstrated 4.6 lb/in adhesion strength to the unpainted fiberglass fairing. Adhesion strength was observed to increase as a function of time. The covers were analyzed and experimentally tested to demonstrate their ability to maintain integrity under anticipated vehicle ascent pressure loads and to not impede firing of the drogue chute mortars. Testing included vacuum testing and a mortar fire test. Tape covers were layed-up on thin Teflon sheets to facilitate installation on the vehicle. Custom cut foam insulation board was used to fill mortar hole and separation joint cavities and provide support to the applied tape covers. Flight test results showed that the tape covers remained adhered during flight

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis

Due to the unpredictable course and heterogenous treatment response in multiple sclerosis (MS), there is a clear need for biomarkers that reflect disease activity in the clinical follow-up of these patients. Neurofilaments are neuron-specific components of the cytoskeleton that can be assayed in different body compartments. They have been explored as potential biomarkers for many years. Neurofilament light chain (NF-L) appears the most promising biomarker in MS patients, and there is now little doubt that NF-L should have a role in the follow-up of MS patients. Newer assays and techniques for NF-L detection available in serum samples confirms the usefulness of NF-L as a biomarker. Nevertheless, there is still a need for prospective studies, and studies to determine clinical useful cut-off values. This review evaluates the strengths and weaknesses of NF-L as a biomarker in patients with MS